Targets › TBAT1
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: the race on TBAT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institute of Tropical Medicine, Belgium | Acoziborole Adenosine transporter 1 (TbAT1) inhibitor for treatment of gambiense human African trypano | TBAT1 | Phase 3 | Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense | Dec 2026 |
Trypanosomiasis; African, Due to Trypanosoma Brucei Gambiense, Gambiense (1)
small molecule (1)
Institute of Tropical Medicine, Belgium (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.